Integral Diagnostics Ltd is primarily active in the healthcare industry. With a focus on precision radiology, the company provides a broad range of diagnostic imaging services including X-rays, ultrasounds, CT scans, and more. Integral Diagnostics operates in various sectors within healthcare, including hospitals, medical centers, and specialty clinics. With their high-quality imaging equipment and expert radiologists, Integral Diagnostics plays a crucial role in assisting healthcare professionals in accurate and timely diagnoses. As a leading player in the healthcare industry, Integral Diagnostics Ltd continues to contribute to the advancement of medical imaging and patient care.

The main competitors of Integral Diagnostics Ltd in the market include companies like Sonic Healthcare Ltd, Healius Ltd, and Capitol Health Ltd.

Integral Diagnostics Ltd is a leading medical imaging and radiology service provider in Australia and New Zealand. Established in 2008, the company has quickly grown to become a trusted name in the healthcare industry. With a strong focus on delivering high-quality diagnostic services, Integral Diagnostics utilizes advanced imaging technologies to assist in the accurate detection and diagnosis of various medical conditions. The company prides itself on its team of expert radiologists and state-of-the-art facilities, ensuring patients receive the best possible care. Integral Diagnostics continues to expand its network of clinics, striving to make diagnostic services more accessible to patients across the region.

Integral Diagnostics Ltd has achieved several significant milestones since its establishment. The company has successfully expanded its services and reach, becoming one of the leading providers of radiology and nuclear medicine services in Australia and New Zealand. Integral Diagnostics Ltd has also demonstrated consistent growth and financial success over the years. Additionally, the company has made strategic acquisitions, such as Cape Radiology and Global Diagnostics, further strengthening its position in the market. Integral Diagnostics Ltd continues to invest in advanced technology and quality patient care, striving to deliver exceptional diagnostic imaging services to its customers.

Integral Diagnostics Ltd is primarily present in Australia and New Zealand.

Integral Diagnostics Ltd represents values of excellence, innovation, and integrity. With a strong corporate philosophy emphasizing patient care and diagnostic accuracy, Integral Diagnostics aims to provide the highest quality medical imaging and radiology services. The company's commitment to advanced technology and continuous improvement ensures accurate diagnoses, timely results, and exceptional patient outcomes. By investing in cutting-edge equipment, fostering a collaborative environment, and prioritizing professional development, Integral Diagnostics maintains its status as a trusted provider in the medical imaging field. With a focus on patient-centric care, the company consistently delivers superior diagnostic services, making it a preferred choice for medical professionals and patients alike.

Analysts currently set an average price target of 3,34 AUD for the Integral Diagnostics stock (median: 3,37 AUD), implying +49,6 % versus the latest price. The consensus is based on 16 analyst ratings.

Integral Diagnostics Analītiķu cenu mērķi 2026

16 analysts currently rate the Integral Diagnostics stock: 14 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Integral Diagnostics to generate revenue of 798,59 M AUD and earnings per share of 0,13 AUD.

Integral Diagnostics Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the Integral Diagnostics share trades at 1,37 EUR (2,23 AUD).

The Integral Diagnostics share (IDX.AX) is listed on 1 stock exchanges, including: ASX (IDX.AX).

Integral Diagnostics Ltd is a leading Australian diagnostic company that offers medical imaging and pathology services. The company was founded in 1998 and has been listed on the Australian stock exchange since 2015. Integral Diagnostics' business model is based on providing high-quality diagnostic services needed by physicians and other healthcare providers to make accurate diagnoses and ensure the best possible treatment for their patients. Integral Diagnostics operates several business divisions, including radiology services, pathology services, and clinical trials. In the radiology field, the company offers a wide range of diagnostic imaging services, including X-rays, ultrasound, MRI, and CT scans. The company has over 50 radiology practices throughout Australia and a growing presence in New Zealand. The company also offers specialized radiology services such as oncology imaging and intervention, as well as training and workshops for medical staff. Integral Diagnostics also operates a pathology division, which offers a comprehensive range of pathology services including clinical chemistry, hematology, histopathology, and microbiological testing. Integral Diagnostics' pathology services are used for diagnosing diseases and monitoring patients undergoing treatment. In the pathology division, Integral Diagnostics operates 17 laboratories throughout Australia. In addition to radiology and pathology services, Integral Diagnostics also conducts clinical trials. The company provides support to medical researchers in conducting clinical trials and evaluating the effectiveness of new treatment methods. Integral Diagnostics' clinical trials cover a wide range of medical specialties, including oncology, cardiology, and neurology. Integral Diagnostics has a robust IT system that allows for the electronic transmission of patient data and images. The company also operates an online platform through which physicians and medical professionals can access their patient data and images. This facilitates information exchange among doctors and enables quicker diagnosis and treatment of patients. Integral Diagnostics' business model is based on providing high-quality and efficient diagnostic services. The products offered by Integral Diagnostics are essential tools for physicians and medical professionals to make accurate diagnoses and ensure the best possible treatment for patients. When it comes to search engine optimization (SEO), it is important to use relevant keywords that users enter when searching for medical diagnostic services. These may include keywords such as "radiology services," "pathology services," and "clinical trials." The text should also provide the reader with a clear overview of Integral Diagnostics' business model without being too promotional.

gaidāmā apgrozījums Integral Diagnostics ir 798,59 M AUD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa Integral Diagnostics ir 38,94 M AUD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

Integral Diagnostics cenas un peļņas rādītājs (P/E) pašlaik ir 17,77. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Integral Diagnostics akcijas vērtību.

Integral Diagnostics cenas un apgrozījuma rādītājs (P/S) pašlaik ir 0,87. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Integral Diagnostics akcijas vērtības mērs.

Integral Diagnostics Eulerpool kvalitātes rādītājs ir 5/10.

Integral Diagnostics ISIN ir AU000000IDX2. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

Integral Diagnostics tikeris ir IDX.AX. Tikeris tiek izmantots Integral Diagnostics akciju tirdzniecībai biržā.

Pēdējo 12 mēnešu laikā Integral Diagnostics maksāja dividendes 0,09 AUD apmērā. Tas atbilst aptuveni 4,16 % dividendes ražībai. Nākamajos 12 mēnešos Integral Diagnostics plāno maksāt dividendes 0,11 AUD apmērā.

Integral Diagnostics pašreizējā dividendu rentabilitāte ir 4,16 %.

Integral Diagnostics maksā dividendes, kas tiek sadalītas mēnešos , , , .

Integral Diagnostics pēdējo 10 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,11 AUD. Tas atbilst dividendes ražībai 5,12 %.

Integral Diagnostics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Integral Diagnostics apmērā 0,06 AUD, kas tika izmaksāta , tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija .

Pēdējās dividendes izmaksa notika .

Gadā 2025, Integral Diagnostics izmaksāja 0,09 AUD dividendes.

Integral Diagnostics dividendes tiek izmaksātas AUD.